Novartis将其印度股卖给一个15 900万美元的财团,经过战略审查后退出市场。 Novartis sells its India unit to a consortium for $159M, exiting the market after a strategic review.

诺华将将其在印度的70.68%股权全部出售给由WaveRise投资,克莱斯资本和Two Infinity合作伙伴领导的财团, 价格约为1.59亿美元, 标志着其退出印度. Novartis is selling its entire 70.68% stake in Novartis India to a consortium led by WaveRise Investments, ChrysCapital, and Two Infinity Partners for approximately $159 million, marking its exit from India. 这项交易须经管理部门批准,包括一项强制性公开报价,即购买最多26%的剩余股份,每股860.64美分,加价3.6%。 The deal, subject to regulatory approval, includes a mandatory open offer to buy up to 26% of remaining shares at ₹860.64 each, a 3.6% premium. 这笔交易是经过两年战略审查后进行的,符合诺华公司关于扩大美国业务的重点,包括2025年4月宣布的230亿美元投资计划。 The transaction follows a two-year strategic review and aligns with Novartis’s focus on expanding its U.S. operations, including a $23 billion investment plan announced in April 2025. 印度无生产厂,但销售诸如Voveran之类的药物的诺华公司股价在此次公告上了近20%,达到996.50卢比. Novartis India, which has no manufacturing in India and markets drugs like Voveran, saw its shares surge nearly 20% to ₹996.50 on the announcement.